A selection of major announcements

1. Yuexiu Real Estate Affiliated successfully competed for the World Scenic Phase II plot in Tianhe District, Guangzhou with 4.394 billion yuan

$YUEXIU PROPERTY (00123.HK)$An announcement was issued. On December 28, 2023, Guangzhou Hongtai Real Estate Development Co., Ltd. (“Guangzhou Hongtai”) successfully competed for AT1003010, AT1003075, AT1003082, Huangyun Road, Tianhe District, Guangzhou (“Guangzhou Tianhe District World Scenic Phase II Plot”) through a public listing of RMB 4393.5 billion through public listing.

2. Tencent Holdings spent HK$1.02 billion to repurchase 3.45 million shares on December 28

$TENCENT (00700.HK)$An announcement was announced that on December 28, 2023, the company spent HK$1,002 billion to repurchase 3.45 million shares at a repurchase price of HK$285-295.4 per share. It is worth noting that Tencent has repurchased over HK$1 billion in a single day for 3 consecutive days, with a cumulative total of over HK$3 billion.

3. Clover Biotech announces positive data from SCB-219M phase I clinical trial of the targeted drug for tumor chemotherapy-related thrombocytopenia (CIT)

$CLOVER BIO-B (02197.HK)$An announcement was issued to obtain positive preliminary data on safety, efficacy, and pharmacokinetics in a phase I clinical trial evaluating a new class of drugs SCB-219M. SCB-219M is an innovative bispecific Fc fusion protein-targeting drug containing a thrombocytopenia (TPO-RA) modeptide produced by CHO cells for thrombocytopenia (“CIT”) caused by chemotherapy in cancer patients.

4. Fu Hong Hanlin: Hans Type® was approved for marketing in Indonesia to treat widespread small cell lung cancer

$HENLIUS (02696.HK)$Announcement. Recently, PT Kalbio Global Medika, a subsidiary of the company's commercial partner KGBio, received drug registration approval, and the company's self-developed anti-PD-1 monoclonal antibody Hans Form® was approved by the Indonesian Food and Drug Administration (BPOM) for the treatment of extensive small cell lung cancer (ES-SCLC). The trade name is Zerpidio®. This is the first time that Hans-like® has been approved for marketing in overseas markets, and Hans-like® has also become the first domestically produced anti-PD-1 monoclonal antibody approved for marketing in Southeast Asian countries.

Important matters

$CHANGJIU HLDGS (06959.HK)$Proposed global sale of 50.54 million shares expected to be listed on January 9, 2024

$TJCD (02515.HK)$The proposed global sale of 53.95 million shares is expected to be listed on January 16, 2024

$CONCORD HC GP (02453.HK)$The proposed global sale of 394.202 million shares is expected to be listed on January 9, 2024

$CHINARES PHARMA (03320.HK)$: China Resources Pharmaceutical Business Proposes to Increase Registered Capital

$SDHS NEW ENERGY (01250.HK)$It is proposed to lay out power batteries, next-generation breakthrough energy storage devices, and system-related businesses to promote the integration of wind and solar storage and charging

$YESTAR HEALTH (02393.HK)$Abnormal stock price fluctuations. A total of 64.14 million shares held by non-executive director He Zhenfa were sold on the market and trading resumed tomorrow

$BROAD HOMES (02163.HK)$: Hangzhou Yuanda received investment from BOC to increase capital by 200 million yuan, and the company's shareholding fell to 66.37%

$HOPSON DEV HOLD (00754.HK)$: Total repayment of US$224.5 million of maturing notes, and no other offshore notes due before the end of the year and still outstanding

$CHINA JINMAO (00817.HK)$It is proposed to introduce partners to increase capital for Xi'an Runmao

Pharmaceutical Innovation

$LEPU BIO-B (02157.HK)$: MRG003 is used to treat recurrence/metastatic nasopharyngeal cancer (R/M NPC) who completed the enrollment of key registered phase IIb clinical trials

$CR MEDICAL (01515.HK)$: Gate District Hospital IOT agreement will end on January 1st

$IVD MEDICAL (01931.HK)$The strategic cooperation agreement signed with Heisenmekang Shanghai on a strategic cooperation in the blood coagulation products business has been completed

Acquisition and sale

$KANGJI MEDICAL (09997.HK)$Proposed sale of all shares in a subsidiary company for 366 million yuan

$GREENLAND HK (00337.HK)$Plans to sell 49% of Guangzhou Green Control Real Estate's shares for 440 million yuan

$CHINA JINMAO (00817.HK)$Acquired 56.67% of Aidido's shares and cooperated in the development of the Hangzhou plot

$CHINAHONGQIAO (01378.HK)$The subsidiary bought a plot of land in Zouping, Shandong at a total cost of 240 million yuan

Repurchase cancellation

$HSBC HOLDINGS (00005.HK)$2.5 million shares were repurchased at HK$156 million on December 27

$AIA (01299.HK)$On December 28, HK$134 million was spent to buy back 1.9872 million shares

$CLOUDR (09955.HK)$Proposed repurchase of no more than HK$80 million of company shares

$HAIER SMARTHOME (06690.HK)$On December 28, it spent 356.915 million yuan to buy back 1.7 million A-shares

$ESR (01821.HK)$On February 28, 2.5 million shares were purchased at HK$26.68 million

$CONCORD NE (00182.HK)$32.89 million shares were repurchased at HK$20.63 million on December 28

$WUXI BIO (02269.HK)$On December 28, it cost HK$19.43 million to buy back 673,000 shares

$COSCO SHIP HOLD (01919.HK)$On December 28, it spent HK$16.3821 million to repurchase 2.105 million shares

$YUM CHINA (09987.HK)$On December 27, $2 million was spent to buy back 47,900 shares

$SWIRE PACIFIC A (00019.HK)$On December 28, it cost HK$124.814 million to repurchase 190,000 shares

$ZHONGYU ENERGY (03633.HK)$On December 28, it cost HK$11.27 million to buy back 2 million shares

$ZHONGSHENG HLDG (00881.HK)$5.4 million shares cancelled on December 28

edit/ruby